Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228553 · ClinicalTrials.gov registry record · Phase 3
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
A Phase 3 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 743
- Enrollment target
NCT00228553 is a Phase 3 study that has completed, run by Cephalon. The registered enrollment target is 743 participants.
The verdict
NCT00228553, a Phase 3 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 743 participants
- Enrollment target
Study Summary
A 12 Month, Open-Label, Flexible Dosage Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder
Interventions
- DRUG Armodafinil 100 to 250 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 743 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00228553
The ClinicalTrials.gov registry entry for NCT00228553 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 743 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Armodafinil 100 to 250 mg/day is the first listed.
NCT00228553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00228553 about?
NCT00228553 is a clinical study titled "Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness". A 12 Month, Open-Label, Flexible Dosage Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder
What is the current status of trial NCT00228553?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 743 participants. The study started on 2004-05. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00228553?
The interventions under investigation include: Armodafinil 100 to 250 mg/day (DRUG).
Who is sponsoring clinical trial NCT00228553?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.